Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.45
-0.8000-1.21%
Pre-market: 67.482.03+3.10%04:01 EDT
Volume:1.74M
Turnover:114.39M
Market Cap:9.22B
PE:-28.66
High:66.80
Open:66.80
Low:65.09
Close:66.25
52wk High:95.49
52wk Low:34.38
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.85
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.80
PE(LYR):-5,367.83

Loading ...

Arrowhead Pharmaceuticals (ARWR) Joins Larger Indexes After EU Approval, Is It Still Cheap?

Simply Wall St.
·
Jul 06

Is EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

Simply Wall St.
·
Jul 02

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 02

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 30

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 30

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and CSL (OtherCMXHF)

TIPRANKS
·
Jun 30

Arrowhead Pharmaceuticals Posts Cardiometabolic R&D Webinar Presentation

Reuters
·
Jun 30

Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jun 27

Arrowhead receives MAA in the EU for REDEMPLO

TIPRANKS
·
Jun 23

Arrowhead says EU grants marketing authorization for REDEMPLO in adult FCS patients

Reuters
·
Jun 23

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for Redemplo® (Plozasiran) to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
Jun 23

Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update

Simply Wall St.
·
Jun 20

Arrowhead Pharmaceuticals to host cardiometabolic R&D webinar in 2026 Summer Series

Reuters
·
Jun 18

Arrowhead Pharma director Matthew Gregory Cohen files initial beneficial ownership statement

Reuters
·
Jun 18

Movement Alert|Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum

Market Focus
·
Jun 18

Arrowhead Pharmaceuticals Is Maintained at Market Perform by Leerink Partners

Dow Jones
·
Jun 17

Arrowhead Pharmaceuticals : Leerink Partners Raises Target Price to $72 From $61

THOMSON REUTERS
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board

TIPRANKS
·
Jun 17

Arrowhead Pharmaceuticals appoints Vida Ventures’ Matt Cohen to board

Reuters
·
Jun 17